ACC 2022: EMPULSE Analysis Reveals Consistent Benefits for Empagliflozin in Heart Failure Regardless of Impairment at Baseline
Benefits were observed for multiple domains of the Kansas City Cardiomyopathy Questionnaire
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.